Chow CK, Atkins ER, Hillis GS, Nelson
MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing
quadruple combination of quarter doses of blood pressure medicines versus
standard dose monotherapy in patients with hypertension (QUARTET): a phase 3,
randomised, double-blind, active-controlled trial. Lancet
2021;398(10305):1043-52. https://www.ncbi.nlm.nih.gov/pubmed/34469767
Cohn JN, Pfeffer MA, Rouleau J, Sharpe
N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic
inhibition with sustained-release moxonidine in patients with heart failure
(MOXCON). Eur J Heart Fail 2003;5(5):659-67. https://www.ncbi.nlm.nih.gov/pubmed/14607206
Drawz PE, Agarwal A, Dwyer JP, Horwitz
E, Lash J, Lenoir K, et al. Concordance Between Blood Pressure in the Systolic
Blood Pressure Intervention Trial and in Routine Clinical Practice. JAMA Intern
Med 2020;180(12):1655-63. https://www.ncbi.nlm.nih.gov/pubmed/33044494
Lasserson DS, Buclin T, Glasziou P. How
quickly should we titrate antihypertensive medication? Systematic review
modelling blood pressure response from trial data. Heart 2011;97(21):1771-5.
https://www.ncbi.nlm.nih.gov/pubmed/21586424
Ponikowski P, Voors AA, Anker SD, Bueno
H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure: The Task Force for the diagnosis
and treatment of acute and chronic heart failure of the European Society of
Cardiology (ESC)Developed with the special contribution of the Heart Failure
Association (HFA) of the ESC. Eur Heart J 2016;37(27):2129-200. https://www.ncbi.nlm.nih.gov/pubmed/27206819
Sheppard JP, Stevens S, Stevens R,
Martin U, Mant J, Hobbs FDR, et al. Benefits and Harms of Antihypertensive
Treatment in Low-Risk Patients With Mild Hypertension. JAMA Intern Med
2018;178(12):1626-34. https://www.ncbi.nlm.nih.gov/pubmed/30383082
Sprint Research Group, Lewis CE, Fine
LJ, Beddhu S, Cheung AK, Cushman WC, et al. Final Report of a Trial of Intensive
versus Standard Blood-Pressure Control. N Engl J Med 2021;384(20):1921-30. https://www.ncbi.nlm.nih.gov/pubmed/34010531
Whelton PK, Carey RM, Aronow WS, Casey
DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,
Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report
of the American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines. Hypertension 2018;71(6):e13-e115. https://www.ncbi.nlm.nih.gov/pubmed/29133356
Williams B, MacDonald TM, Morant S, Webb
DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and
doxazosin to determine the optimal treatment for drug-resistant hypertension
(PATHWAY-2): a randomised, double-blind, crossover trial. Lancet
2015;386(10008):2059-68. https://www.ncbi.nlm.nih.gov/pubmed/26414968
Williams B, Mancia G, Spiering W,
Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the
management of arterial hypertension. Eur Heart J 2018;39(33):3021-104. https://www.ncbi.nlm.nih.gov/pubmed/30165516
Zhang W, Zhang S, Deng Y, Wu S, Ren J,
Sun G, et al. Trial of Intensive Blood-Pressure Control in Older Patients with
Hypertension. N Engl J Med 2021;385(14):1268-79. https://www.ncbi.nlm.nih.gov/pubmed/34491661
